Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT-SLE phase 3 study of upadacitinib in adults with moderate to severe systemic lupus erythematosus
MOH_2023-07-24_012844Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in systemic lupus erythematosus (SLE) (7 arms), sponsored by AbbVie Inc. Started Jul 2023; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on MOH_2023-07-24_012844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-07-24_012844.